News

SCB Perspectives: BioFabUSA Fall Summit Preview

Washington, DC (September 18, 2018) — SCB Secretary Richard McFarland discusses the BioFabUSA 2018 Fall Summit, which focuses on leveraging operational strategies for transitioning engineered tissues and organs from research and clinical trials to commercialization and patient adoption learned from the successes and best practices of pioneers in the biofabrication community, and why standards have a prominent place in the agenda as a critical facilitator of tissue engineering product availability. [...]


SCB Perspectives: New Progress in RMTM, Scaffolds, and Cell Transportation Standards

Washington, DC (September 14, 2018) — As part of the new SCB Perspectives series, SCB President Dr. Jiwen Zhang discusses several SCB standards projects she’s excited about and how these projects can ultimately contribute to safer regenerative medicine products for patients. [...]


SCB Engages with Regenerative Medicine Standards Development Stakeholders at ASGCT

Washington, DC (May 20, 2018) — On May 16, 2018, as part of the 21st Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Chicago, Illinois, Nexight Group and SCB conducted a workshop with stakeholders in the regenerative medicine community to gather input on the development of processes and tools that will be used to improve the identification, prioritization, and feasibility assessment of standards needs for regenerative medicine. [...]


Sharing the Standards Development Mission at ISCT 2018

Washington, DC (May 7, 2018) — On May 2–5, 2018 in Montreal, Nexight Group and SCB participated in the annual meeting of the International Society for Cellular Therapy (ISCT), a global society of more than 1,500 clinicians, researchers, regulators, technologists, and industry partners representing more than 50 countries with a shared vision of translating cellular therapy into safe, effective therapies to improve patients’ lives worldwide. SCB President Jiwen Zhang was invited to speak about SCB and its efforts to advance standards in regenerative medicine in a session entitled “Progress in the World of Standards for Cell and Gene Therapies.” [...]


SCB Co-Convenes Rapid Microbial Testing Methodology (RMTM) Workshop

Washington, DC (April 11, 2018) — On April 10, 2018, SCB, the National Institute of Standards and Technology (NIST), BioFabUSA, and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) hosted a workshop to gather input from the regenerative medicine community on advancing rapid microbial testing methodology (RMTM) technologies and standards for sterility testing. [...]


Nexight Group and SCB Hold Second Webinar on Regenerative Medicine Standards

Washington, DC (March 13, 2018) — Nexight Group and SCB today held their second webinar aimed at increasing the awareness of available and potential standards and the benefits they can bring to the regenerative medicine community. As part of the FDA-funded project to identify process recommendations and criteria to identify and prioritize standards needs and advance standards for regenerative medicine therapies, the Overview Of Standards For The Regenerative Medicine Landscape webinar featured an overview of the landscape of available standards and a case study on sterility testing requirements. [...]


SCB and Nexight Group Publish Landmark Regenerative Medicine Standards Landscape Report

Washington, DC (February 28, 2018) – With input from more than 30 academic institutions, standards development organizations (SDOs), and other industry experts, Nexight Group and The Standards Coordinating Body (SCB) published The Regenerative Medicine Standards Landscape—developed with funding from the U.S. Food and Drug Administration (FDA)—a first-of-its-kind report that outlines nearly 200 standards currently relevant to regenerative medicine therapies and identifies opportunities for future standards development in the field. [...]


Nexight Group and SCB Hold Webinar on Regenerative Medicine Standards

Washington, DC (December 30, 2017) — In December 2017, Nexight Group and SCB held the first in a series of webinars aimed at increasing the awareness of available and potential standards and their benefit to the regenerative medicine community. As part of the FDA-funded project to identify process recommendations and criteria to identify and prioritize standards needs and advance standards for regenerative medicine therapies, the The Need for Standards in Regenerative Medicine webinar featured case studies demonstrating how the development of standards positively influenced work in two different fields of regenerative medicine. [...]


Significant Efforts Underway to Lay the Foundation for Standards Development in Regenerative Medicine Therapies  

Washington, DC (October 25, 2017) – On September 27, 2017, the U.S. Food and Drug Administration awarded a one-year contract to Nexight Group to engage with experts to recommend processes and outline a strategic plan for developing standards in regenerative medicine and advanced therapies. The Standards Coordinating Body for Gene, Cell, and Regenerative Medicines and Cell-based Drug Discovery (SCB) has partnered with Nexight to provide subject matter technical support for this effort. [...]


Newly Created Standards Coordinating Body Seeks to Advance Development and Establishment of Regenerative Medicine Standards 

Washington, DC (Marketwired - Jan 19, 2017) The international Standards Coordinating Body for regenerative medicines (SCB), in coordination with the Alliance for Regenerative Medicine (ARM), today announced its formal launch as a public-private partnership for coordinating, prioritizing and supporting standards that advances process, measurement and analytical techniques to support the global availability of products across the gene and gene-modified cell therapy, cell therapy, cell-based drug discovery, tissue engineering and biomaterials sectors. [...]


SCB and NIST to Work Together to Advance Development and Establishment of Industry-Wide Standards

Washington, DC (September 19, 2016) – The Standards Coordinating Body for Gene, Cell and Regenerative Medicines and Cell-based Drug Discovery (SCB) announced today it has entered into a memorandum of understanding (MOU) with the National Institute of Standards and Technology’s (NIST) Material Measurement Laboratory (MML) to advance the development of industry-wide standards for cell therapy, gene therapy, regenerative medicine and cell-based drug discovery. [...]